Gyre Therapeutics, Inc. (NASDAQ:GYRE) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$23M raised · US$9 a share · Jefferies +1 Dealers: Jefferies (lead), H.C. Wainwright & Co. Use of proceeds: Advance Phase 2 trial of F351 in MASH-associated liver fibrosis in the US, R&D, manufacturing and scale-up, working capital and general corporate purposes | May 29, 2025 |
| Public offering of common stock Announced: Jefferies +1 Dealers: Jefferies (lead), H.C. Wainwright & Co. Use of proceeds: Advance Phase 2 trial of F351 in MASH-associated liver fibrosis in the US, R&D, manufacturing and scale-up, working capital and general corporate purposes | May 22, 2025 |